Revolution Medicines (RVMD) Projected to Post Earnings on Wednesday

Key Points

• Revolution Medicines is expected to report its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($1.14) per share and $0.50 million in revenue.
• The stock price of Revolution Medicines has decreased by 0.7% and the company has a market cap of $6.89 billion, with current stock prices opening at $37.01.
• Analysts maintain a consensus rating of "Buy" for Revolution Medicines, with an average target price of $68.91 despite some recent adjustments by brokerage firms.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.14) per share and revenue of $0.50 million for the quarter.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the previous year, the firm posted ($0.70) earnings per share. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Down 1.7%

NASDAQ RVMD traded down $0.64 during trading on Friday, hitting $36.63. 978,549 shares of the stock traded hands, compared to its average volume of 1,474,059. The company has a market capitalization of $6.82 billion, a P/E ratio of -9.16 and a beta of 1.16. The firm has a 50-day simple moving average of $38.71 and a 200-day simple moving average of $38.92. Revolution Medicines has a 12-month low of $29.17 and a 12-month high of $62.40.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC lifted its stake in shares of Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company's stock worth $5,529,000 after acquiring an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock worth $10,615,000 after acquiring an additional 37,345 shares during the last quarter. Finally, Nextech Invest Ltd. lifted its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on RVMD shares. Needham & Company LLC restated a "buy" rating and set a $57.00 price target on shares of Revolution Medicines in a report on Tuesday, June 24th. The Goldman Sachs Group started coverage on Revolution Medicines in a report on Tuesday, July 15th. They set a "buy" rating and a $65.00 price target for the company. Guggenheim restated a "buy" rating and set a $80.00 price target on shares of Revolution Medicines in a report on Wednesday, June 25th. HC Wainwright restated a "buy" rating and set a $72.00 price target (down previously from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Oppenheimer raised their price target on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $68.91.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.